Effects of Intercept pathogen reduction treatment on extended cold storage of apheresis platelets.
Blood Banks
/ standards
Blood Coagulation
/ radiation effects
Blood Platelets
/ metabolism
Blood Preservation
/ methods
Blood-Borne Pathogens
/ radiation effects
Cryopreservation
/ methods
Flow Cytometry
/ methods
Furocoumarins
/ pharmacology
Humans
Photosensitizing Agents
/ pharmacology
Plasma
/ radiation effects
Plateletpheresis
/ methods
Refrigeration
/ methods
Thrombelastography
/ methods
cold storage
pathogen reduction technology
platelets
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
23
03
2020
revised:
24
07
2020
accepted:
24
07
2020
pubmed:
10
12
2020
medline:
6
7
2021
entrez:
9
12
2020
Statut:
ppublish
Résumé
Platelets pose the greatest transfusion-transmitted infectious risk among blood products. Refrigeration of platelets can mitigate bacterial contamination and extend platelet shelf life. Implementation of pathogen reduction technologies (PRTs) at blood banks has become increasingly popular to protect against emerging and reemerging infectious diseases. In this study, we sought to evaluate the effects of Intercept PRT on platelets collected on different platforms and cold-stored for up to 21 days in plasma and platelet additive solution (PAS). Double-dose apheresis platelets were collected with use of a Trima or Amicus system into either 100% plasma or 65% InterSol PAS/35% plasma and split equally between two bags. One bag served as control, while the other received Intercept PRT treatment. Bags were stored unagitated in the cold and evaluated on Days 1, 7, 14, and 21 to assess platelet metabolism, activation, aggregation, and clot formation and retraction. By Day 14 of storage, lactate levels reached approximately 13 mmol/L for all samples irrespective of Intercept treatment. Mean clot firmness dropped from the 62.2- to 67.5-mm range (Day 1) to the 28.4- to 51.3-mm range (Day 21), with no differences observed between groups. Clot weights of Intercept-treated Trima/plasma samples were significantly higher than control by Day 14 of storage (P = .004), indicating a reduced clot retraction function. Intercept treatment caused a higher incidence of plasma membrane breakdown in plasma-stored platelets (P = .0013; Trima/plasma Day 14 Control vs Intercept). Intercept treatment of platelets and subsequent cold storage, in plasma or PAS, results in comparable platelet metabolism platelets for up to 14 days of storage but altered clotting dynamics. Pathogen-reduced platelets with an extended shelf life would be beneficial for the deployed setting and would greatly impact transfusion practice among civilian transfusion centers.
Sections du résumé
BACKGROUND
Platelets pose the greatest transfusion-transmitted infectious risk among blood products. Refrigeration of platelets can mitigate bacterial contamination and extend platelet shelf life. Implementation of pathogen reduction technologies (PRTs) at blood banks has become increasingly popular to protect against emerging and reemerging infectious diseases. In this study, we sought to evaluate the effects of Intercept PRT on platelets collected on different platforms and cold-stored for up to 21 days in plasma and platelet additive solution (PAS).
METHODS
Double-dose apheresis platelets were collected with use of a Trima or Amicus system into either 100% plasma or 65% InterSol PAS/35% plasma and split equally between two bags. One bag served as control, while the other received Intercept PRT treatment. Bags were stored unagitated in the cold and evaluated on Days 1, 7, 14, and 21 to assess platelet metabolism, activation, aggregation, and clot formation and retraction.
RESULTS
By Day 14 of storage, lactate levels reached approximately 13 mmol/L for all samples irrespective of Intercept treatment. Mean clot firmness dropped from the 62.2- to 67.5-mm range (Day 1) to the 28.4- to 51.3-mm range (Day 21), with no differences observed between groups. Clot weights of Intercept-treated Trima/plasma samples were significantly higher than control by Day 14 of storage (P = .004), indicating a reduced clot retraction function. Intercept treatment caused a higher incidence of plasma membrane breakdown in plasma-stored platelets (P = .0013; Trima/plasma Day 14 Control vs Intercept).
CONCLUSIONS
Intercept treatment of platelets and subsequent cold storage, in plasma or PAS, results in comparable platelet metabolism platelets for up to 14 days of storage but altered clotting dynamics. Pathogen-reduced platelets with an extended shelf life would be beneficial for the deployed setting and would greatly impact transfusion practice among civilian transfusion centers.
Substances chimiques
Furocoumarins
0
Photosensitizing Agents
0
amotosalen
K1LDZ0VBC0
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
167-177Informations de copyright
© 2020 AABB.
Références
Levy JH, Neal MD, Herman JH. Bacterial contamination of platelets for transfusion: strategies for prevention. Crit Care. 2018;22(1):271.
Bacterial Contamination of Platelets. The Centers for Disease Control and Prevention. 2013. http://www.cdc.gov/bloodsafety/bbp/bacterial-contamination-of-platelets.html. Accessed January 5, 2020.
Irsch J, Lin L. Pathogen inactivation of platelet and plasma blood components for transfusion using the INTERCEPT blood system™. Transfus Med Hemother. 2011;38(1):19-31.
Ketter PM, Kamucheka R, Arulanandam B, Akers K, Cap AP. Platelet enhancement of bacterial growth during room temperature storage: mitigation through refrigeration. Transfusion. 2019;19(52):1479-1489.
Becker GA, Tuccelli M, Kunicki T, Chalos MK, Aster RH. Studies of platelet concentrates stored at 22 C and 4 C. Transfusion. 1973;13(2):61-68.
Johnson L, Tan S, Wood B, Davis A, Marks DC. Refrigeration and cryopreservation of platelets differentially affect platelet metabolism and function: a comparison with conventional platelet storage conditions. Transfusion. 2016;56(7):1807-1818.
Nair PM, Pandya SG, Dallo SF, et al. Platelets stored at 4 degrees C contribute to superior clot properties compared to current standard-of-care through fibrin-crosslinking. Br J Haematol. 2017;178(1):119-129.
NasrEldin E. Effect of cold storage on platelets quality stored in a small containers: Implications for pediatric transfusion. Pediatr Hematol Oncol J. 2017;2(2):29-34.
Reddoch KM, Montgomery RK, Rodriguez AC, et al. Endothelium-derived inhibitors efficiently attenuate the aggregation and adhesion responses of refrigerated platelets. Shock. 2016;45(2):220-227.
Reddoch KM, Pidcoke HF, Montgomery RK, et al. Hemostatic function of apheresis platelets stored at 4 degrees C and 22 degrees C. Shock. 2014;41(Suppl 1):54-61.
Torres Filho IP, Torres LN, Valdez C, Salgado C, Cap AP, Dubick MA. Refrigerated platelets stored in whole blood up to 5 days adhere to thrombi formed during hemorrhagic hypotension in rats. J Thromb Haemost. 2017;15(1):163-175.
Valeri CR. Circulation and hemostatic effectiveness of platelets stored at 4 C or 22 C: studies in aspirin-treated normal volunteers. Transfusion. 1976;16(1):20-23.
Wu X, Darlington DN, Montgomery RK, et al. Platelets derived from fresh and cold-stored whole blood participate in clot formation in rats with acute traumatic coagulopathy. Br J Haematol. 2017;179(5):802-810.
Bynum JA, Meledeo MA, Getz T, et al. Bioenergetic profiling of platelet mitochondria during storage: 4°C storage extends platelet mitochondrial function and viability. Transfusion. 2016;56(Suppl 1):S76-S84.
Bauckman C. FDA action makes blood product more accessible to warfighters in combat 2019 [updated June 1, 2019; cited 2019]. https://mrdc.amedd.army.mil/index.cfm/media/news_releases/2019/blood_product_more_accessible
Macher S, Sipurzynski-Budrass S, Rosskopf K, et al. Function and activation state of platelets in vitro depend on apheresis modality. Vox Sang. 2010;99:332-340.
Jilma-Stohlawetz P, Eichelberger B, Horvath M, Jilma B, Panzer S. In vitro platelet function of platelet concentrates prepared using three different apheresis devices determined by impedance and optical aggregometry. Transfusion. 2009;49:1564-1568.
Skripchenko A, Kurtz J, Moroff G, Wagner SJ. Platelet products prepared by different methods of sedimentation undergo platelet activation differently during storage. Transfusion. 2008;48:1469-1477.
Singh Y, Sawyer LS, Pinkoski LS, et al. Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion. 2006;46(7):1168-1177.
Mathai J, Resmi KR, Sulochana PV, Sathyabhama S, Baby Saritha G, Krishnan LK. Suitability of measurement of swirling as a marker of platelet shape change in concentrates stored for transfusion. Platelets. 2006;17(6):393-396.
Bertolini MS. A multicenter evaluation of reproducibility of swirling in platelet concentrates. Transfusion. 1994;34(9):796-801.
Reddoch-Cardenas KM, Montgomery RK, Lafleur CB, Peltier GC, Bynum JA, Cap AP. Cold storage of platelets in platelet additive solution: an in vitro comparison of two Food and Drug Administration-approved collection and storage systems. Transfusion. 2018;58(7):1682-1688.
Nair PM, Meledeo MA, Xiaowu W, et al. Effect of extended platelet storage on platelet metabolism and clot retraction. Blood. 2019;134(Suppl 1):2450.
Zucker M, Borrelli J. Reversible alteration in platelet morphology produced by anticoagulants and by cold. Blood. 1954;28:524-534.
Jutzi M, Taleghani BM, Rueesch M, Amsler L, Buser A. Nationwide implementation of pathogen inactivation for all platelet concentrates in Switzerland. Transfus Med Hemother. 2018;45(3):151-156.
Atreya C, Glynn S, Busch M, et al. Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (commentary, P. 3026). Transfusion. 2019;59(9):3002-3025.
Benjamin RJ, Braschler T, Weingand T, Corash LM. Hemogivilance monitoring of platelet septic reactions with effective bacterial protection systems. Transfusion. 2017;57(12):2946-2957.
Stubbs JR, Tran SA, Emery RL, et al. Cold platelets for trauma-associated bleeding: regulatory approval, accreditation approval, and practice implementation-just the "tip of the iceberg.". Transfusion. 2017;57(12):2836-2844.
Kobzar G, Mardla V, Samel N. Lactate is a possible mediator of the glucose effect on platelet inhibition. Platelets. 2014;25:239-245.
Bertolini F, Porretti L, Lauri E, Rebulla P, Sirchia G. Role of lactate in platelet storage lesion. Vox Sang. 1993;65:194-198.
Kofoed KF, Naesh O, Hindberg I, Winther K. Attenuated platelet aggregation in the presence of high concentrations of lactate. Thromb Res. 1991;63:549-552.
Picker SM, Speer R, Gathof BS. Functional characteristics of buffy-coat PLTs photochemically treated with amotosalen-HCl for pathogen inactivation. Transfusion. 2004;44(3):320-329.
van der Meer PF, Bontekoe IJ, Daal BB, de Korte D. Riboflavin and UV light treatment of platelets: a protective effect of platelet additive solution? Transfusion. 2015;55(8):1900-1908.
Getz TM, Montgomery RK, Bynum JA, Aden JK, Pidcoke HF, Cap AP. Storage of platelets at 4°C in platelet additive solutions prevents aggregate formation and preserves platelet functional responses. Transfusion. 2016;56(6):1320-1328.
Slichter SJ, Corson J, Jones MK, et al. Exploratory studies of extended storage of apheresis platelets in a platelet additive solution (PAS). Blood. 2014;123(2):271-280.
Golebiewska EM, Poole AW. Platelet secretion: from haemostasis to wound healing and beyond. Blood Rev. 2015;29:153-162.
Six KR, Devloo R, Compernolle V, Feys HB. Impact of cold storage on platelets treated with Intercept pathogen inactivation. Transfusion. 2019;59(8):2662-2671.
Marini I, Aurich K, Jouni R, et al. Cold storage of platelets in additive solution: the impact of residual plasma in apheresis platelet concentrates. Haematologica. 2019;104:207-214.
Reddoch-Cardenas KM, Montgomery RK, Lafleur CB, Peltier GC, Bynum JA, Cap AP. Cold storage of platelet additive solution: an in vitro comparison of two Food and Drug Administration-approved collection and storage systems. Transfusion. 2018;58(7):1682-1688.
Sandgren P, Hansson M, Gulliksson H, Shanwell A. Storage of buffy-coat-derived platelets in additive solutions at 4 °C and 22 °C: flow cytometry analysis of platelet glycoprotein expression. Vox Sang. 2007;93:27-36. https://doi.org/10.1111/j.1423-0410.2007.00912.x
Stivala S, Gobbato S, Infanti L, et al. Amotosalen/ultraviolet A pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance. Haematologica. 2017;102(10):1650-1660. https://doi.org/10.3324/haematol.2017.164137
Osman, A., Hitzler, W. E., Meyer, C. U., Landry, P., Corduan, A., Laffont, B., Provost, P. Effects of pathogen reduction systems on platelet microRNAs, mRNAs, activation, and function. Platelets 2015;26(2):154-63.
Ranucci M, Baryshnikova E. Sensitivity of viscoelastic tests to platelet function. J Clin Med. 2020;9(1):189.
Ruiz R. FDA grants South Texas Blood & Tissue Center first license for new process that triples shelf life of critically needed platelets [monograph on the Internet]. 2020. https://www.globenewswire.com/news-release/2020/02/28/1992715/0/en/FDA-grants-South-Texas-Blood-Tissue-Center-first-license-for-new-process-that-triples-shelf-life-of-critically-needed-platelets.html. Accessed April 22, 2020.